Recurrent GI Bleeding and Surgery Following the Initial Response to Imatinib Therapy in GIST of the Stomach

1. Miettinen M, Lasota J: Gastroinstestinal stromal tumors—Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1–12, 2001CrossRefPubMedGoogle Scholar

2. Kreiker J, Daou R, Aftimos G: Gastric stromal tumors: Presentation of two cases with immunohistochemical study. Review of the literature. Leb Med J 50:226–236, 2002Google Scholar

3. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Silberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumors. Lancet Oncol 3:655–664, 2002CrossRefPubMedGoogle Scholar

4. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP: Excisional surgery for cancer cure: Therapy at a cost. Lancet Oncol 4:760–768, 2003Google Scholar

5. Baum M: Does surgery disseminate or accelerate cancer?. Lancet 347:260, 1996Google Scholar

6. Sturgeon C, Chejfec G, Espat NJ: Gastrointestinal stromal tumours: A spectrum of disease. Surg Oncol 12:21–26, 2003Google Scholar

7. Savage DG, Antman KH: Imatinib mesylate—A new oral targeted therapy. N Engl J Med 346:683–693, 2002CrossRefPubMedGoogle Scholar

8. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480, 2002CrossRefPubMedGoogle Scholar

9. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056, 2001CrossRefPubMedGoogle Scholar

10. Yamamoto S, Kubo S, Shuto T, Yamamoto T, Hirohashi K, Tanaka H, Takemura S, Kanazawa A, Kinoshita H: Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases. J Gastroenterol 38:896–899, 2003Google Scholar

11. Sawaki A, Ohashi K, Yamao K, Inada K, Shimizu Y, Matsuura A, Nakamura T, Suzuki T, Hara K, Okubo K, Ohno R: Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor. J Gastroenterol 38:690–694, 2003Google Scholar

12. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors of survival. Ann Surg 231:51–58, 2000CrossRefPubMedGoogle Scholar

13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880, 2001CrossRefPubMedGoogle Scholar

14. Fortner JG: Inadvertent spread of cancer at surgery. J Clin Oncol 53:191–196, 1993Google Scholar

15. Pollock RE, Torth JA: Cancer-induced immunosuppression: Implications for therapy?. Semin Surg Oncol 5:414–419, 1989Google Scholar

16. Holmgren L, O’Reilly M, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153, 1995Google Scholar